# Snickpick Investment

> Snickpick Investment is a VC fund in Seoul backing Biotechnology, Medical and Pharmaceutical. See 11 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Seoul, South Korea
- Total investments: 11
- Last investment: Feb 2026
- Lead investor: 9%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/sneak-peek-investments
- Website: http://sneakpeeki.com

Snickpick Investment is an investment management company for the bio-healthcare industry.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 45% |
| Medical | 4 | 36% |
| Pharmaceutical | 4 | 36% |
| Health Care | 3 | 27% |
| Software | 2 | 18% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 7 | 64% |
| Seed | 1 | 9% |
| Series A | 1 | 9% |
| Funding Round | 1 | 9% |
| Venture - Series Unknown | 1 | 9% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Galux | Galux provides molecular design technology focusing on discovering and developing novel drugs for incurable and rare diseases using its AI-based drug design platform technologies. | $29M | Series B | Feb 09, 2026 |  |
| Willog | As a fast-growing startup, Willog provides a “item-level condition monitoring” that innovates the supply chain of sensitive, perishable or valuable goods where condition monitoring is required, and its efforts are to create a transparent and connected logistics flow. Based on its patented sensor technology and its cloud-based software, Willog helpscompanies gain seamless visibility down to the item-level and control over their shipments across their supply chain so they can have condition foresights and insights to improve their bottom line.Willog acquired 25 enterprise customers including MNCs like Hyundai Motor Group and DHL Express since its establishment. Willog is rapidly expanding its presence in various industries including bio-pharmaceutical, fresh food, and special logistics, where condition monitoring is key to business continuity. Going forward, while strengthening its leadership position in Korea, Willog will accelerate global expansion with partnerships in America, Kazakhstan, and Malaysia. |  | Series B | Feb 03, 2026 |  |
| MediMabBio | MediMabBio platform uses systems biology combined with sophisticated immunological solutions to identify significantly improving immuno-oncology drugs that can actively target a range of solid tumors. The antibody discovery I-O platform brings the advantages of rational drug design to large molecule therapeutic development. | $17.8M | Series B | Oct 24, 2025 |  |
| Trioar | Trioar is a biotechnological research company that manufacture pharmaceutical products and drugs. | $16.2M | Series B | Jul 17, 2025 |  |
| Dotter | Dotter is a manufacturing company that designs and produces biodegradable optical coherence tomography devices to diagnose and treat cardiovascular diseases. The company also develops next-generation OCT equipment, an optical imaging device that can create a synergy effect when inserting stents. | $7K |  | Dec 27, 2024 |  |
| Dotter | Dotter is a manufacturing company that designs and produces biodegradable optical coherence tomography devices to diagnose and treat cardiovascular diseases. The company also develops next-generation OCT equipment, an optical imaging device that can create a synergy effect when inserting stents. | $9.8M | Series B | Dec 27, 2024 |  |
| J2H Biotech | J2H Biotech is a bio-venture company focusing on the development of small-molecule drugs for the treatment of intractable rare diseases. | $26.2M | Venture - Series Unknown | Jul 14, 2021 |  |
| ATsens | ATsens is suggesting comprehensive way to care the health of human being. Heart of the body is the Heart | $7.7M | Series A | Jan 27, 2021 |  |
| Primoris Therapeutics | Primoris Therapeutics is a medical research and development center. | $2.8M | Seed | Jan 01, 2021 |  |
| CORELINESOFT | CORELINESOFT develops medical software products. | $8.3M | Series B | Jul 23, 2020 |  |

10 of 11 investments shown.

## Co-investors
- [BNH Investment](https://shizune.co/investors/profile/bnh-investment) — VC Fund, 4 deals together
- [KB Investment](https://shizune.co/investors/profile/kbinvest) — VC Fund, 4 deals together
- [Dayli Partners](https://shizune.co/investors/profile/dayli-partners) — VC Fund, 3 deals together
- [LSK Investment](https://shizune.co/investors/profile/lsk-investment) — VC Fund, 3 deals together
- [Murex Partners](https://shizune.co/investors/profile/murex-partners) — VC Fund, 3 deals together
- [Clarevoyant Ventures](https://shizune.co/investors/profile/clarevoyant-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Snickpick Investment invest in?

Snickpick Investment invests primarily in Biotechnology, Medical and Pharmaceutical startups, most often at Series B and Seed stage. Most of the 11 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Snickpick Investment last invest?

The most recent investment recorded for Snickpick Investment closed in Feb 2026. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co